These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1511119)

  • 41. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy.
    Sasaki K; Matsumura K; Murakami T; Tsuji T
    Oncology; 1992; 49(2):147-53. PubMed ID: 1574251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
    Markiewski M; Domagała W
    Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proliferation markers in non-Hodgkin's lymphoma. A comparative study between cytophotometric quantitation of Ki-67 and flow cytometric proliferation index on fine needle aspirates.
    Katz RL; Wojcik EM; el-Naggar AK; Ordonez NG; Johnston DA
    Anal Quant Cytol Histol; 1993 Jun; 15(3):179-86. PubMed ID: 8347257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Determination of estrogen receptors in cytological smears of breast carcinoma biopsy samples using monoclonal antibodies (ER-ICA monoclonal)].
    Marković-Glamocak M
    Lijec Vjesn; 1989; 111(4-5):150-3. PubMed ID: 2770402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor.
    Buxant F; Anaf V; Simon P; Fayt I; Noël JC
    Breast Cancer Res Treat; 2002 Sep; 75(1):1-3. PubMed ID: 12500929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors.
    Hayashi Y; Fukayama M; Koike M; Kaseda S; Ikeda T; Yokoyama T
    Acta Pathol Jpn; 1993 Jun; 43(6):313-9. PubMed ID: 8346708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
    Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
    J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody.
    Weidner N; Moore DH; Vartanian R
    Hum Pathol; 1994 Apr; 25(4):337-42. PubMed ID: 8163266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer.
    Goodson WH; Moore DH; Ljung BM; Chew K; Florendo C; Mayall B; Smith HS; Waldman FM
    Breast Cancer Res Treat; 1998 May; 49(2):155-64. PubMed ID: 9696398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.
    Bardenstein DS; Char DH; Kaleta-Michaels S; Kroll SM
    Curr Eye Res; 1991 May; 10(5):479-84. PubMed ID: 1889233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Presurgical determination of estrogen receptor status using immunocytochemically stained fine needle aspirate smears in patients with breast cancer.
    McClelland RA; Berger U; Wilson P; Powles TJ; Trott PA; Easton D; Gazet JC; Coombes RC
    Cancer Res; 1987 Nov; 47(22):6118-22. PubMed ID: 2444337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proliferation in pituitary adenomas: measurement by MAb KI 67.
    Kitz K; Knosp E; Koos WT; Korn A
    Acta Neurochir Suppl (Wien); 1991; 53():60-4. PubMed ID: 1803886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
    Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
    Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the Cal antibody in the detection of malignant cells in fine needle aspirates from breast lumps.
    Holley MP; Clough DG; Duguid HL; Cuschieri A
    Clin Oncol; 1983 Dec; 9(4):325-30. PubMed ID: 6198121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67.
    Morimura T; Kitz K; Budka H
    Acta Neuropathol; 1989; 77(3):276-82. PubMed ID: 2922990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proliferative activity in invasive breast carcinoma: a comprehensive comparison of MIB-1 immunocytochemical staining in aspiration biopsies to image analytic, flow cytometric and histologic parameters.
    Ostrowski ML; Pindur J; Laucirica R; Chakraborty S; Ramzy I
    Acta Cytol; 2001; 45(6):965-72. PubMed ID: 11726126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.
    Fernando IN; Powles TJ; Dowsett M; Ashley S; McRobert L; Titley J; Ormerod MG; Sacks N; Nicolson MC; Nash A
    Virchows Arch; 1995; 426(2):155-61. PubMed ID: 7757286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models.
    van Weerden WM; Moerings EP; van Kreuningen A; de Jong FH; van Steenbrugge GJ; Schröder FH
    Cell Prolif; 1993 Jan; 26(1):67-75. PubMed ID: 8439590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method.
    Alexiev BA
    Diagn Cytopathol; 1996 Nov; 15(4):277-81. PubMed ID: 8982580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.